How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,010 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

261. Treatment of HIV-1-positive adults with antiretroviral therapy (interim update)

to start in TB/HIV co infection 99 8.1.3 References 100 8.2 Hepatitis B and C virus co-infection 102 When to start ART? 102 8.2.2 Hepatitis B 102 8.2.3 Hepatitis C 104 8.2.4 References 104 8.3 HIV-related cancers 105 8.3.1 When to start ART? 105 8.3.2 What to start 105 8.3.3 Opportunistic infection prophylaxis in HIV-associated malignancy 106 8.3.4 Other considerations from the BHIVA guidelines for HIV-associated malignancies [1] 106 8.3.5 References 107 8.4 HIV-associated neurocognitive impairment 108 (...) to treat hepatitis B and C 8.2.2 Hepatitis B 8.2.2.1 When to start antiretroviral therapy in HBV co-infection 8.2.2.1.1 Recommendations ? We recommend individuals with HIV and hepatitis B virus (HBV) co-infection are treated with fully suppressive ART inclusive of anti-HBV active antivirals, regardless of CD4 cell count (1A). ? We recommend individuals with HIV and HBV co-infection who have an HBV-DNA =2000 IU/mL and/or evidence of more than minimal fibrosis (Metavir =F2) are treated with fully

2017 British HIV Association

262. mCME project V.2.0: randomised controlled trial of a revised SMS-based continuing medical education intervention among HIV clinicians in Vietnam Full Text available with Trip Pro

questions, (2) daily linked readings, (3) links to online CME courses and (4) feedback messages describing the performance of the participant relative to the group. Control participants had equal access to the online CME courses. Our primary endpoint was utilisation of the online CME courses; secondary endpoints were self-study behaviour, performance on a standardised medical exam and job satisfaction.From 121 total HIV clinicians in the three provinces, 106 (87.6%) enrolled, and 48/53 intervention (90 (...) %) and 47/53 control (89%) participants completed the endline evaluations. Compared with controls, intervention participants were more likely to use the CME courses (risk ratio (RR) 2.3, 95% CI 1.4 to 3.8, accounting for 83% of course use (P<0.001)). Intervention participants increased self-study behaviours over controls in terms of use of medical textbooks (P<0.01), consulting with colleagues (P<0.01), searching on the internet (P<0.001), using specialist websites (P=0.02), consulting the Vietnam HIV

2018 BMJ global health Controlled trial quality: predicted high

263. HIV and STI testing among Indigenous women and women who inject drugs

provided HIV testing and pre- and post-test counselling. Women’s- only needle exchange services were also provided at workshops whenever possible. Participants received grocery store gift cards for being tested, for returning for STI and HIV test results, and for attending each of the four educational workshops (10). Over the course of three years, the WORKS intervention engaged 562 participants – 68% of whom were current or former injection drug users. HIV and STI testing rates were high (...) HIV and STI testing among Indigenous women and women who inject drugs RAPID RESPONSE SERVICE | #105, MAY 2016 1 Questions What programs and services have been shown to be effective in increasing HIV and STI testing among Indigenous women and women who inject drugs? References 1. Orchard TR, Druyts E, McInnes CW , Clement K, Ding E, Fernandes KA et al. Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. AIDS Care 2010 March;22(3):324-31. 2. Lally MA

2016 Ontario HIV Treatment Network

264. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana Full Text available with Trip Pro

antiretroviral therapy throughout the course of the study, and similar chemotherapeutic regimens were recommended for all patients, regardless of subtype or HIV status (six to eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone; or cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). There was no difference in 1-year mortality among patients not infected with HIV and patients infected with HIV (unadjusted analysis, 52.9% v 37.1%; hazard ratio [HR], 0.73; P = .33 (...) Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana Botswana has a high prevalence of HIV infection. Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)-an AIDS-defining cancer-in the country.This study used a prospective cancer registry to identify patients with a new diagnosis of NHL reporting for specialty cancer care

2018 Journal of global oncology

265. Improving healthcare providers? face-to-face interactions with clients living with or at-risk for HIV

) – in particular, the user’s health literacy level. Health literacy is “the ability to access, understand, evaluate and communicate information as a way to promote, maintain and improve health in a variety of settings across the life-course” (13). More than half of Canadians do not meet the minimum literacy requirements to manage their health needs (14). For persons at higher risk of HIV, and for those already living with HIV, poor health literacy interferes with their ability to fully understand HIV risk (...) Improving healthcare providers? face-to-face interactions with clients living with or at-risk for HIV RAPID RESPONSE SERVICE | #111, AUGUST 2016 1 RAPID RESPONSE SERVICE THE ONTARIO HIV TREATMENT NETWORK Question • What face-to-face interventions have proven effective in helping providers educate clients and improve their health literacy? References 1. Price-Haywood EG, Harden- Barrios J, Cooper LA. Comparative effectiveness of audit-feedback versus additional physician communication training

2016 Ontario HIV Treatment Network

266. Odefsey (emtricitabine / rilpivirine / tenofovir alafenamide) - HIV-1

) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 January 2015. The applicant applied for the following indication: treatment of adults and adolescents aged 12 years and older weighing at least 35 kg infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load = 100,000 HIV 1 RNA copies/mL (see (...) Odefsey (emtricitabine / rilpivirine / tenofovir alafenamide) - HIV-1 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 28 April 2016 EMA/335723/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Odefsey International non-proprietary name: emtricitabine / rilpivirine / tenofovir alafenamide Procedure

2016 European Medicines Agency - EPARs

267. Public health guidance on HIV and STI prevention among men who have sex with men

syndrome ART Antiretroviral treatment ARV Antiretroviral CDC US Centers for Disease Control and Prevention CD4 Cluster Differentiation 4 EACS European AIDS Clinical Society EASL European Association on the Study of the Liver ECDC European Centre for Disease Prevention and Control EEA European Economic Area EMIS European Men-who-have-sex-with-men Internet Survey EU European Union HASTE Highest Attainable Standard of Evidence HIV Human immunodeficiency virus HPV Human papilloma virus HSV2 Herpes simplex (...) and STI transmission among MSM, address the needs of MSM who are living with HIV, as well as promote sexual health among all MSM. ? Vaccinations: Promote and deliver vaccination to protect against hepatitis A and B. Consider vaccination for human papilloma virus (HPV). ? Condoms: Provide easily accessible condoms and condom-compatible lubricants and promote their effective use. ? HIV and STI testing: Provide voluntary and confidential HIV and STI counselling and testing via a variety of modalities

2015 European Centre for Disease Prevention and Control - Public Health Guidance

268. Reminder systems for people living with HIV

Reminder systems for people living with HIV Reminder systems for people living with HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Reminder systems for people living with HIV Reminder systems for people living with HIV , Questions What types of telephone, computer and other app-based interventions have been effective in reminding people living with HIV to attend medical appointments and adhere to antiretroviral medications? What types of telephone, computer and other (...) app-based interventions have been effective in reminding people living with HIV to test/retest for STIs and subsequently notify their partners when testing positive? Key take-home messages Text messaging, smart phone applications and cell phone counselling are all effective in promoting adherence to antiretroviral therapy (1-4). Text messaging and smart phone reminders are more effective if they are personal in nature, and if they evoke or require a response from the participant (2;4-6). Text

2015 Ontario HIV Treatment Network

269. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost (...) Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? | Sexually Transmitted Infections by The case of India has been seen as a model of an intelligent and integrated use of data for an evidence-based response to the HIV/AIDS epidemic ( ). Avahan, the India HIV/AIDS

2018 Sexually Transmitted Infections blog

270. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost (...) Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? | Sexually Transmitted Infections by The case of India has been seen as a model of an intelligent and integrated use of data for an evidence-based response to the HIV/AIDS epidemic ( ). Avahan, the India HIV/AIDS

2018 Sexually Transmitted Infections blog

271. The prevalence and process of pediatric HIV disclosure: A population-based prospective cohort study in Zimbabwe. Full Text available with Trip Pro

the virus to others (i.e. "full disclosure"). Older children were more likely to know their status. Among the non-disclosed caregivers at baseline, nearly 60% of these children learned their HIV status over the course of the 12-month study period, but only 17.1% learned how they were infected and that they can transmit the virus to others. Most caregivers were satisfied with their child's disclosure experience. Caregivers who had not disclosed their child's HIV status to the child worried (...) The prevalence and process of pediatric HIV disclosure: A population-based prospective cohort study in Zimbabwe. The objective of this study was to estimate the prevalence of pediatric HIV disclosure in rural Zimbabwe and track the process of disclosure over time.We recruited a population-based sample of 372 caregivers of HIV-positive children ages 9 to 15 to participate in a survey about disclosure. Using data from this cross-sectional sample, we then identified a prospective cohort of 123

2019 PLoS ONE

272. Malaria care-seeking behaviour among HIV-infected patients receiving antiretroviral treatment in South-Eastern Nigeria: A cross-sectional study. Full Text available with Trip Pro

in self-medication; 39.2% went to drug shops, and only 22.6% visited HIV/AIDS care centres. Almost 40% waited more than 24 hours before initiating treatment. Most (60.3%), reported taking recommended artemisinin-based combination treatments (ACT) but a significant minority took only paracetamol (25.6%) or herbal remedies (3.5%). Most (80%) finished their chosen course of treatment; and completion of treatment was significantly associated with the frequency of suspected malaria occurrence (p = 0.03 (...) Malaria care-seeking behaviour among HIV-infected patients receiving antiretroviral treatment in South-Eastern Nigeria: A cross-sectional study. This study assesses malaria prevention and treatment behaviour among people living with HIV/AIDS (PLWHA) in Owerri, South Eastern Nigeria. Although Nigeria bears one of the world's largest burdens of both malaria and HIV, there is almost no research studying how co-infected patients manage their care. We systematically sampled 398 PLWHA receiving care

2019 PLoS ONE

273. HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. Full Text available with Trip Pro

HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. TB remains a leading cause of mortality and morbidity in sub-Saharan Africa, due to the HIV epidemic. As TB treatment is lengthy, the completion of the full course of treatment may be especially challenging for young people. We therefore aimed to identify the extent of and reasons underlying loss to follow-up from TB treatment among young people in Cape Town. Accordingly, we (...) reviewed the outcomes of young people treated for TB in Cape Town during 2009-2013, across three age groups: younger adolescents (10-14 years); older adolescents; (15-19 years) and young adults (20-24 years). We employed logistic regression analysis to identify risk factors for loss from TB care. 23,737 patients aged 10-24 were treated for drug sensitive TB over the study period. Of these, the HIV co-infection prevalence was 18.5% for younger adolescents, 12.9% for older adolescents and 33.1% for young

2019 PLoS ONE

274. Properties of a brief assessment tool for longitudinal measurement of cognition in people living with HIV. Full Text available with Trip Pro

Properties of a brief assessment tool for longitudinal measurement of cognition in people living with HIV. Mild cognitive impairment is common in chronic HIV infection and there is concern that it may worsen with age. Distinguishing static impairment from on-going decline is clinically important, but the field lacks well-validated cognitive measures sensitive to decline and feasible for routine clinical use. Measures capable of detecting improvement are also needed to assess interventions (...) . The objective of this study is to estimate the extent of change on repeat administration of three different forms of a brief computerized cognitive assessment battery (B-CAM) developed for assessing cognitive ability in the mildly-impaired to normal range in people living with HIV. We hypothesized no change over a six-month period in people on effective antiretroviral therapy.102 HIV+ individuals completed a set of computerized cognitive tasks on three occasions over a six-month period. Rasch analysis

2019 PLoS ONE

275. Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambézia Province, Mozambique. Full Text available with Trip Pro

the benefits of joining CASGs earlier in one´s treatment course. Finally, greater efforts should be made to accelerate the scale-up of viral load capacity and HIV resistance monitoring. (...) Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambézia Province, Mozambique. Mozambique has made significant gains in addressing its HIV epidemic, yet adherence to visit schedules remains a challenge. HIV programmatic gains to date could be impaired if adherence and retention to ART remains low. We investigate individual factors associated with non-adherence to ART pick-up in Mozambique.This

2019 PLoS ONE

276. "I am still negative": Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa. Full Text available with Trip Pro

"I am still negative": Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa. Women remain highly vulnerable to HIV infection in sub-Saharan Africa, with female sex workers (FSWs) facing some of the highest rates of HIV. Oral pre-exposure prophylaxis (PrEP) has the potential to reduce new infections among populations at highest risk and end-user perspectives of actual use in 'real-world' settings are critical to informing PrEP (...) implementation. This paper presents findings from serial in-depth interviews (IDIs) conducted with FSW participants during the course of the Treatment And Prevention for Sex workers (TAPS) Demonstration Project in South Africa, exploring the lived experiences and perceptions of taking up and using PrEP. This research provides insight into risks and responsibilities facing FSWs perceived as prominent drivers in taking up and using PrEP, how PrEP was adopted to mitigate risk or ameliorate realities

2019 PLoS ONE

277. Genetic variations in the host dependency factors ALCAM and TPST2 impact HIV-1 disease progression. (Abstract)

Genetic variations in the host dependency factors ALCAM and TPST2 impact HIV-1 disease progression. Recently, the activated leukocyte cell adhesion molecule (ALCAM) and tyrosylprotein sulfotransferase 2 (TPST2) have been identified as important host dependency factors (HDFs) for in-vitro HIV-1 replication. To determine whether these genes play a role in HIV-1 pathogenesis, we analysed whether naturally occurring genetic variations were associated with the clinical course of infection.Single (...) nucleotide polymorphisms (SNPs) in ALCAM and TPST2 were analysed in a cohort of 304 HIV-1-infected men who have sex with men and survival analysis was used to determine their effect on the outcome of untreated HIV-1 infection. Flowcytometry was used to determine the effect of SNPs on CD4 T-cell activation prior to HIV-1 infection and 1 and 5 years after infection. In-vitro HIV-1 infections were performed to analyse the effect of the SNPs on HIV-1 replication.We observed that the minor allele of rs1344861

2020 AIDS

278. Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. Full Text available with Trip Pro

Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. Many people living with HIV (PLWH) have comorbidities which are risk factors for severe coronavirus disease 2019 (COVID-19) or have exposures that may lead to acquisition of severe acute respiratory distress syndrome coronavirus 2. There are few studies, however, on the demographics, comorbidities, clinical presentation, or outcomes of COVID-19 (...) in people with HIV.To evaluate risk factors, clinical manifestations, and outcomes in a large cohort of PLWH with COVID-19.We systematically identified all PLWH who were diagnosed with COVID-19 at a large hospital from 3 March to 26 April 2020 during an outbreak in Massachusetts. We analyzed each of the cases to extract information including demographics, medical comorbidities, clinical presentation, and illness course after COVID-19 diagnosis.We describe a cohort of 36 PLWH with confirmed COVID-19

2020 AIDS

279. Long-term experience and outcomes of programmatic antiretroviral therapy for HIV-2 infection in Senegal, West Africa. (Abstract)

Long-term experience and outcomes of programmatic antiretroviral therapy for HIV-2 infection in Senegal, West Africa. Programmatic treatment outcome data for people living with HIV-2 in West Africa, where the virus is most prevalent, are scarce.HIV-2-infected adults initiating or receiving ART through the Senegalese national AIDS program were invited to participate in this prospective, longitudinal observational cohort study. We analyzed HIV-2 viral loads, CD4 counts, antiretroviral drug (...) in the Senegalese national AIDS program are initiating ART earlier in the course of disease, and more modern therapeutic regimens have improved outcomes among those receiving therapy. Despite these achievements, HIV-2 treatment remains sub-optimal, and significant challenges to improving care remain.© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

2020 Clinical Infectious Diseases

280. Endothelial dysfunction in South African youth living with perinatally acquired HIV on antiretroviral therapy. (Abstract)

adjustment.Even after adjusting for physiologic differences, YLPHIV appear to be at increased risk for ED compared to age-matched youth without HIV. These findings have important implications for the life course of YLPHIV who may be at increased risk of premature CVD and complications.© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. (...) Endothelial dysfunction in South African youth living with perinatally acquired HIV on antiretroviral therapy. HIV and antiretroviral therapy (ART) confer cardiovascular disease (CVD) risk in adults living with HIV. Few studies have assessed endothelial dysfunction (ED), an early marker of subclinical CVD risk, in youth living with perinatally acquired HIV (YLPHIV).Using peripheral arterial tonometry (EndoPAT), we compared ED in YLPHIV and age-matched youth without HIV. A reactive hyperaemic

2020 Clinical Infectious Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>